In vitro and in vivo role of heat shock protein 90 in Amphotericin B resistance of Aspergillus terreus

Clinical Microbiology and Infection

Volumn 19, Issue 1, 2013, Pages 50-55

  Blum, G ^a   Kainzner, B ^a   Grif, K ^a   Dietrich, H ^b   Zelger, B ^c   Sonnweber, T ^a   Lass Florl C ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Innsbruck Central Animal Experiment Station   (Austria)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Amphotericin B; Antifungal drug resistance; Aspergillus terreus; Heat shock protein 90; In vitro antifungal susceptibility

Indexed keywords

AMPHOTERICIN B; CYCLOSPORIN A; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; POLYENE ANTIBIOTIC AGENT; TACROLIMUS; TANESPIMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS TERREUS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FUNGAL GENETICS; GENE EXPRESSION PROFILING; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; MURINAE; MUS;

EID: 84871622723     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03848.x     Document Type: Article

References (30)

1. Wingard J, Ribaud P, Schlamm H, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112: 2309-2312.
2. Segal B. Aspergillosis. N Engl J Med 2009; 360: 1870-1884.
3. Richardson M, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008; 14 (suppl 4): 5-24.
4. Lass-Flörl C, Rath P, Niederwieser D et al. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect 2000; 46: 31-35.
5. Lass-Flörl C, Mayr A. Diagnosing invasive fungal diseases - limitations of microbiological diagnostic methods. Expert Opin Med Diagn 2009; 3: 1-10.
6. Blum G, Perkhofer S, Grif K et al. A 1-year Aspergillus terreus surveillance study at the University Hospital of Innsbruck: molecular typing of environmental and clinical isolates. Clin Microbiol Infect 2008; 14: 1146-1151.
7. Lass-Flörl C, Perkhofer S, Mayr A. Invitro susceptibility tesing in fungi: a global perspective on a variety of methods. Mycoses 2010; 53: 1-11.
8. Walsh T, Petraitis V, Petraitiene R et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to Amphotericin B. J Infect Dis 2003; 188: 305-319.
9. Lass-Flörl C, Cuenca-Estrella M, Denning D, Rodriguez-Tudela J. Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. Med Mycol 2006; 44 (suppl 1): 319-325.
10. Sokol-Anderson ML, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 1986; 154: 76-83.
11. Pierce AM, Pierce HD Jr, Unrau AM, Oehlschlager AC. Lipid composition and polyene antibiotic resistance of Candida albicans mutants. Can J Biochem 1978; 56: 135-142.
12. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005; 309: 2185-2189.
13. Cowen L, Singh S, Köhler J et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 2009; 106: 2818-2823.
14. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008; 410: 439-453.
15. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005; 146: 769-780.
16. Matthews RC, Rigg G, Hodgetts S et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003; 47: 2208-2216.
17. Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee WC. Heat shock protein 90: inhibitors in clinical trials. J Med Chem 2010; 53: 3-17.
18. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999; 42: 260-266.
19. LaFayette SL, Collins C, Zaas AK et al. PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog 2010; 6: e1001069.
20. Pallavi R, Roy N, Nageshan R et al. Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem 2010; 285: 37964-37975.
21. Arenderup M, Perkhofer S, Howard SJ et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother 2008; 52: 3504-3511.
22. Pfaffl M. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Adics Res 2001; 29: e45.
23. Lass-Flörl C, Gunsilius E, Gastl G et al. Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol 2004; 42: 4154-4157.
24. Xie Q, Thompson R, Hardy K et al. A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med 2008; 6: 77.
25. van Burik JA, Schreckhise RW, White TC, Bowden RA, Myerson D. Comparison of six extraction techniques for isolation of DNA from filamentous fungi. Med Mycol 1998; 36: 299-303.
26. Bowman J, Abruzzo G, Anderson J et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474-3481.
27. Cowen LE. Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog 2009; 5: e1000471.
28. Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 2007; 5: 418-430.
29. Pachl J, Svoboda P, Jacobs F et al. A randomized, blinded, multicenter trial of lipid-associated Amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42: 1404-1413.
30. Stewart GR, Young DB. Heat-shock proteins and the host-pathogen interaction during bacterial infection. Curr Opin Immunol 2004; 16: 506-510.